Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Buy" from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have earned an average recommendation of "Buy" from the eight analysts that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $59.20.

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Canaccord Genuity Group dropped their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating on the stock in a report on Monday, March 10th. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. HC Wainwright lowered their target price on Arcturus Therapeutics from $63.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Finally, Wells Fargo & Company reduced their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, March 7th.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently added to or reduced their stakes in ARCT. Franklin Resources Inc. boosted its position in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock worth $2,412,000 after purchasing an additional 36,714 shares during the period. Empire Life Investments Inc. boosted its holdings in Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock worth $4,742,000 after buying an additional 128,771 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in Arcturus Therapeutics by 139.7% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company's stock valued at $1,393,000 after buying an additional 47,824 shares in the last quarter. Spire Wealth Management raised its holdings in Arcturus Therapeutics by 393.3% during the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 10,746 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock worth $203,000 after acquiring an additional 3,705 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Remove Ads

Arcturus Therapeutics Stock Up 10.2 %

NASDAQ ARCT traded up $0.91 on Friday, reaching $9.82. The company had a trading volume of 550,984 shares, compared to its average volume of 459,069. The company's fifty day moving average is $14.14 and its 200 day moving average is $17.06. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $45.00. The stock has a market capitalization of $266.32 million, a P/E ratio of -4.42 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million during the quarter, compared to analysts' expectations of $44.64 million. On average, research analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.